Novartis uses the open-source Drupal content management framework for many key websites, including our flagship global site Novartis.com, main country sites, portals for healthcare professionals, and certain product and disease awareness sites.
Drupal gives Novartis the foundations for great audience-focused digital experiences covering company information, campaigns, tools and services. Our commitment to Drupal and the open-source community began in 2014 when corporate websites began migrating to Drupal 7.
In October 2021 Novartis.com relaunched on Drupal 9, joining pilot sites including Novartis Foundation and Novartis Campus on the platform. The Drupal 9 upgrades also included a fresh new design system, audience-first navigation, content improvements and a renewed commitment to accessibility. In the months following, country corporate sites also migrated to Drupal 9.
The corporate web portfolio was upgraded to Drupal 10 in September 2023. Novartis continues to be an active supporter of the Drupal open-source community including sponsorship of DrupalCon Lille in October 2023.
Contribution
As part of Novartis’ ongoing commitment to Drupal, we are actively contributing to the community:
- Clinical Trials module: designed to facilitate the integration and management of clinical trial data within a Drupal website. Leveraging the ClinicalTrials.gov API, this module will allow users to query and import clinical trial data, creating structured node content automatically.
- Big Datatable module: provides a powerful and flexible solution for generating HTML tables from uploaded CSV files. This module is designed to handle large datasets efficiently, making it ideal for sites that need to display extensive tabular data.
Novartis acknowledges the support of Acquia and HCL Technologies in our Drupal journey, especially the dedicated team of developers working behind the scenes.